ASSESSMENT OF EFFICIENCY OF COMBINED PHARMACOTHERAPY FOR IMPERATIVE AND MIXED URINARY DISORDERS IN WOMEN WITH THE INTERVAL SCALE

Introduction. The search for effective drug combinations for treating continental disorders in women is still relevant. The interval scale for assessing lower urinary tract symptoms in women is a simple and convenient tool for monitoring pharmacotherapy. Objective: to evaluate the effectiveness of treatment of imperative and mixed urination disorders in women with alpha1-blockers in combination with nootropic drugs using an interval symptom rating scale.
Materials and methods. Under observation there were 31 patients aged 40 to 73 years who applied to the Center “Urination Pathology” with mixed and imperative disorders of the continent and urinary incontinence. Conservative therapy was carried out with the appointment of alpha1-adrenoblockers, nootropic and metabolic drugs for an average of 5.8 months. The therapeutic effect is recorded using the interval symptom score scale.
Results. After discontinuation of drugs, the overall score on the symptom rating scale decreased by 40.2%, imperative symptoms – by 29.5-50%, and quality of life increased by 19%. In the group of women aged 40-49, with comparable dynamics of symptoms with patients older than 50 years, therapy lasted less. The difference averaged 4.1 months and was associated with a higher frequency in the older age group of vascular, metabolic and neurological disorders that slow down the regulatory processes of urination recovery.
Conclusion. Alpha1-blockers and nootropics are pathogenetically substantiated for the treatment of imperative disorders of urination and urinary incontinence. Evaluation using the interval scale reliably demonstrates their high clinical effectiveness, persistence of the therapeutic effect and the feasibility of application at the stage of selection for surgical treatment.

1. Nygaard I., Barber M.D., Burgio K.L.,Kenton K., Meikle S., Schaffer J., Spino C., Whitehead W.E., Wu J., Brody D.J. Pelvic Floor Disorders Network. Prevalence of Symptomatic Pelvic Floor Disorders in US Woman. JAMA. 2008;300(11):1311-1316.

2. Sacco E., Tienforti D., DAddessi A., Pinto F., Racioppi M., Totaro A., Dagostino D., Marangi F., Bassi P. Social, economic, and health utility considerations in the treatment of overactive bladder. J. Urol. 2010;2:11-24.

3. Аль-Шукри С.Х., Кузьмин И.В. Качество жизни больных с гиперактивностью мочевого пузыря. Урологические ведомости. 2011;1(1):21–26. [Al-Shukri S.H., Kuzmin I.V. Quality of life in patients with overactive bladder. Urologicheskie vedomosti. 2011;1(1):21–26. (In Russian)]

4. Irwin D.E., Milsom I., Hunskaar S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. https://doi.org/10.1016/j.eururo.2006.09.019.

5. Kogan M.I., Zachoval R., Ozyurt C. et al. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin. 2014;30(10):2119–2130. https://doi.org/10.1185/03007995.2014.934794.

6. Gadjieva Z.K. Disturbances of urination: Guidance. Ed. Y.G. Alyaev. M.: GEOTAR-Media, 2010,176 p. (In Russian)

7. Sivkov A.V., Romih V.V., Korshunova E.S., Korshunov M.N. Sovremennye podhody k lecheniju bol’nyh giperaktivnym mochevym puzyrem. Andrologija i genital’naja hirurgija. 2010;(3):6–11. (In Russian)

8. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: Медфорум, 2017. 544 с. [Urology. Russian clinical recommenda-tions. Yu.G. Alyaev, P.V. Glybochko, D.Yu. Pushkar, editors. M.:Medforum, 2017. 554 p. (In Russian)]

9. Guidelines on urinary incontinence. Lucas M.G., Bedretdinova D., Berghmans L.C., et al. EAU pocket guidelines. 2013. p. 175–198.

10. Huang W., Zong H., Zhou X., Zhang Y. Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47(3):457–464. https://doi.org/10.1007/s11255-015-0916-1.

11. Al-Shukri S.H., Pushkar D.Yu., Apolikhin O.I., et al. Imidafenacin for treatment of overactive bladder and urgent urinary incontinence: the results of open-label multicenter randomized controlled clinical trial. Urologiia. 2018;6:20-25. https://dx.doi.org/10.18565/urology.2018.6.20-25. (In Russian)]

12. Khullar V., Amarenco G., Angulo J.C., et al. Efficacy and tolerability of mirabegron, a 3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized EuropeanAustralian Phase 3 Trial. Eur Urol, 2013, 63(2): 283-95.

13. Kasyan G.R., Sukhikh S.O., Pushkar D.Yu. The place of mirabegron in clinical practice. Urologiia. 2017;(6):144–148. (In Russian)

14. Danilov V.V., Eliseeva E.V., Danilov V.V. K voprosu mekhanizma dejstviya a1-adrenoblokatorov. Russian Medical Journal. 2009;2(17):109-113. (In Russian).

15. Kul'chaveniya E.V., Brizhatyuk E.V. Vliyanie α-blokatora Setegis (terazozin) na mikrocirkulyaciyu v stenke mochevogo puzyrya. Russian Medical Journal. 2003;11(4):226-228. (In Russian).

16. Gomberg V.G., Nad' YU.T., Efimova V.V. Primenenie terazozina (Setegis) v lechenii giperaktivnogo mochevogo puzyrya i urgentnoj inkontinencii u pozhilyh zhenshchin. Russian Medical Journal. 2005;13(9):606-607. (In Russian).

17. Danilova T.I., Petrov S.B., Danilov V.V. Nederzhanie mochi pri napryazhenii i al'fa1-adrenoblokatory: teoreticheskoe obosnovanie koncepcii konservativnoj terapii. Effective pharmacotherapy in urology. 2010;4:18-23. (In Russian)

18. Danilov V.V., Danilov V.V. Neurouroscience. Vladivostok:Club of Directors; 2019.V.1.280 p. (In Russian)]

19. Vishnevskij E.L., Pushkar' D.YU., Loran O.B., Danilov V.V., Vishnevskij A.E. Uroflowmetry. M.: Pechatnyj gorod; 2004. рр. 176–183, 183–208, 263. (In Russian).